GLP-1RA are currently being studied in phase 3 trials for the treatment of HFpEF, peripheral artery disease (PAD), diabetic kidney disease (DKD), metabolic liver disorders such as nonalcoholic steatohepatitis (NASH), and neurodegenerative disorders
Retatrutide is administered as a once-weekly subcutaneous injection, similar in delivery to other medicines in this class
Rather than suppressing caloric intake, they may enhance substrate utilization, preserve lean mass, and improve metabolic resiliencefeatures particularly relevant to aging populations, where sarcopenia, osteoporosis, and insulin resistance frequently coexist
When a product claims that a peptide the size of semaglutide crosses your skin from a patch, it is working directly against basic pharmacology, and understanding this one fact makes most patch marketing fall apart on contact, before you even read the ingredient list